ScholarIQanswers from OpenAlex & ORCID
Mark A. Socinski
ResearcherPublications, citations & collaboration network
Mark A. Socinski is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mark A. Socinski have?
ScholarIQindexed works
Mark A. Socinski has 783 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mark A. Socinski have?
ScholarIQcitation count
Mark A. Socinski has 36,990 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mark A. Socinski?
ScholarIQh-index
Mark A. Socinski has an h-index of 84 in OpenAlex.
What is the i10-index of Mark A. Socinski?
ScholarIQi10-index
Mark A. Socinski has an i10-index of 335 in OpenAlex.
What is the ORCID of Mark A. Socinski?
ScholarIQorcid
The ORCID for Mark A. Socinski is on the source record.
What is the OpenAlex record for Mark A. Socinski?
ScholarIQopenalex
The OpenAlex for Mark A. Socinski is on the source record.
What are the most-cited papers on Mark A. Socinski?
ScholarIQmost cited works
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Zeaiter, Walter Bordogna, Bogdana Balas, Óscar Puig, Volkmar Henschel, Sai‐Hong Ignatius Ou
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski